Cargando…
High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction
SIMPLE SUMMARY: Afatinib is used to treat non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation as a second-generation EGFR-tyrosine kinase inhibitor (TKI). We examined the relationship between the trough plasma concentrations of afatinib and adverse effects,...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305619/ https://www.ncbi.nlm.nih.gov/pubmed/34298637 http://dx.doi.org/10.3390/cancers13143425 |